Position/Title: Director (Centre for Applied Neurogenetics (CAN))

Address: The University of British Columbia, 2215 Wesbrook Mall, Vancouver, Canada

Tel:+1-604-8227753 ; Fax: +1-604-8220361




1986-1991 BSc (Hons) Biochemistry, Kings College London, UK

1992-1996 PhD Human Genetics, St. Mary’s Hospital Medical School, Imperial College, London, UK

1997-1999 Senior Fellow, Mayo Clinic Jacksonville, USA


2004-2008 Editorial Board of Movement Disorders

2005-2008 Editorial Board of Neurobiology of Disease

2008-present Editorial Board of Parkinsonism and Related Disorders

2010-present Editorial Board of Journal of Parkinson’s Disease


2005 Jacksonville Business Journal, “Health-Care Hero.” Florida

2008 Mayo Distinguished Investigator Award, Mayo Clinic Jacksonville, Florida

2009 Jacksonville Business Journal, “Health-Care Hero.” Florida

2011 Michael J. Fox Foundation Pritzker Prize nomination, USA

2012 9th Donald Calne Lectureship, Vancouver, Canada


From 335 original publications; total citations: 19,921; h-index: 68

  1. Singleton AB, Farrer M (equally contributing first author), Johnson J, …, Gwinn-Hardy K. alpha- Synuclein locus triplication causes Parkinson’s disease. Science 2003;302:841. (IF: 29.2)
  2. Skipper L, Wilkes K, Toft M, …, Farrer M. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 2004;75:669-677. (IF: 12.3)
  3. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, …, Gasser T. Mutations in LRRK2 cause autosomal- dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607. (IF: 14.4)
  4. Kachergus J, Mata IF, Hulihan M, …, Farrer MJ, Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680. (IF: 12.6)
  5. Lewis J, Melrose H, Bumcrot D, …, Farrer MJ. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 2008;3:19. (IF: 5.0)
  6. Farrer MJ, Hulihan MM, Kachergus JM, …, Wszolek ZK. DCTN1 mutations in Perry syndrome. Nature Genet 2009;41:163-165. (IF: 34.3)
  7. Melrose HL, Dächsel JC, Behrouz B, …, Farrer MJ. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010;40:503-517. (IF: 5.1)
  8. Vilariño-Güell C, Wider C, Ross OA, …, Farrer MJ. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011;89:162-167. (IF: 10.6)
  9. Vilariño-Güell C, Rajput A, Milnerwood AJ, …, Farrer MJ. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 2014;23:1794-1801. (IF: 6.4)
  10. Beccano-Kelly DA, Volta M, Munsie LN, …, Farrer MJ, Milnerwood AJ. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 2015;24:1336-1349. (IF: 6.4)